Literature DB >> 24358984

Ligand binding mode prediction by docking: mdm2/mdmx inhibitors as a case study.

Nagakumar Bharatham1, Kavitha Bharatham, Anang A Shelat, Donald Bashford.   

Abstract

The p53-binding domains of Mdm2 and Mdmx, two negative regulators of the tumor suppressor p53, are validated targets for cancer therapeutics, but correct binding poses of some proven inhibitors, particularly the nutlins, have been difficult to obtain with standard docking procedures. Virtual screening pipelines typically draw from a database of compounds represented with 1D or 2D structural information from which one or more 3D conformations must be generated. These conformations are then passed to a docking algorithm that searches for optimal binding poses on the target protein. This work tests alternative pipelines using several commonly used conformation generation programs (LigPrep, ConfGen, MacroModel, and Corina/Rotate) and docking programs (GOLD, Glide, MOE-dock, and AutoDock Vina) for their ability to reproduce known poses for a series of Mdmx and/or Mdm2 inhibitors, including several nutlins. Most combinations of these programs using default settings fail to find correct poses for the nutlins but succeed for all other compounds. Docking success for the nutlin class requires either computationally intensive conformational exploration or an "anchoring" procedure that incorporates knowledge of the orientation of the central imidazoline ring.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24358984      PMCID: PMC4753531          DOI: 10.1021/ci4004656

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  68 in total

1.  Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.

Authors:  Daniel J Parks; Louis V LaFrance; Raul R Calvo; Karen L Milkiewicz; Juan José Marugán; Pierre Raboisson; Carsten Schubert; Holly K Koblish; Shuyuan Zhao; Carol F Franks; Jennifer Lattanze; Theodore E Carver; Maxwell D Cummings; Diane Maguire; Bruce L Grasberger; Anna C Maroney; Tianbao Lu
Journal:  Bioorg Med Chem Lett       Date:  2006-04-04       Impact factor: 2.823

2.  Impact of conformational flexibility on three-dimensional similarity searching using correlation vectors.

Authors:  Steffen Renner; Christof H Schwab; Johann Gasteiger; Gisbert Schneider
Journal:  J Chem Inf Model       Date:  2006 Nov-Dec       Impact factor: 4.956

3.  Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

Authors:  Ke Ding; Yipin Lu; Zaneta Nikolovska-Coleska; Guoping Wang; Su Qiu; Sanjeev Shangary; Wei Gao; Dongguang Qin; Jeanne Stuckey; Krzysztof Krajewski; Peter P Roller; Shaomeng Wang
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

4.  AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.

Authors:  Oleg Trott; Arthur J Olson
Journal:  J Comput Chem       Date:  2010-01-30       Impact factor: 3.376

5.  Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.

Authors:  Yipin Lu; Zaneta Nikolovska-Coleska; Xueliang Fang; Wei Gao; Sanjeev Shangary; Su Qiu; Dongguang Qin; Shaomeng Wang
Journal:  J Med Chem       Date:  2006-06-29       Impact factor: 7.446

6.  Inactivation of the p53 pathway in retinoblastoma.

Authors:  Nikia A Laurie; Stacy L Donovan; Chie-Schin Shih; Jiakun Zhang; Nicholas Mills; Christine Fuller; Amina Teunisse; Suzanne Lam; Yolande Ramos; Adithi Mohan; Dianna Johnson; Matthew Wilson; Carlos Rodriguez-Galindo; Micaela Quarto; Sarah Francoz; Susan M Mendrysa; R Kiplin Guy; Jean-Christophe Marine; Aart G Jochemsen; Michael A Dyer
Journal:  Nature       Date:  2006-11-02       Impact factor: 49.962

Review 7.  MDM2 inhibitors for cancer therapy.

Authors:  Lyubomir T Vassilev
Journal:  Trends Mol Med       Date:  2006-11-28       Impact factor: 11.951

Review 8.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

9.  Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.

Authors:  Shanghai Yu; Dongguang Qin; Sanjeev Shangary; Jianyong Chen; Guoping Wang; Ke Ding; Donna McEachern; Su Qiu; Zaneta Nikolovska-Coleska; Rebecca Miller; Sanmao Kang; Dajun Yang; Shaomeng Wang
Journal:  J Med Chem       Date:  2009-12-24       Impact factor: 7.446

10.  Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.

Authors:  John G Allen; Matthew P Bourbeau; G Erich Wohlhieter; Michael D Bartberger; Klaus Michelsen; Randall Hungate; Robert C Gadwood; Rick D Gaston; Bruce Evans; Larry W Mann; Michael E Matison; Stephen Schneider; Xin Huang; Dongyin Yu; Paul S Andrews; Andreas Reichelt; Alexander M Long; Peter Yakowec; Evelyn Y Yang; Tani Ann Lee; Jonathan D Oliner
Journal:  J Med Chem       Date:  2009-11-26       Impact factor: 7.446

View more
  15 in total

1.  Comparative evaluation of several docking tools for docking small molecule ligands to DC-SIGN.

Authors:  Gregor Jug; Marko Anderluh; Tihomir Tomašič
Journal:  J Mol Model       Date:  2015-06-04       Impact factor: 1.810

2.  Druggability and Binding Site Interaction Studies of Potential Metabolites Isolated from Marine Sponge Aurora globostellata against Human Epidermal Growth Factor Receptor-2.

Authors:  M Sugappriya; D Sudarsanam; Raj Bhaskaran; Jerrine Joseph; Arumugam Suresh
Journal:  Bioinformation       Date:  2017-08-31

Review 3.  In silico structure-based approaches to discover protein-protein interaction-targeting drugs.

Authors:  Woong-Hee Shin; Charles W Christoffer; Daisuke Kihara
Journal:  Methods       Date:  2017-08-09       Impact factor: 3.608

4.  EDGA: A Population Evolution Direction-Guided Genetic Algorithm for Protein-Ligand Docking.

Authors:  Boxin Guan; Changsheng Zhang; Jiaxu Ning
Journal:  J Comput Biol       Date:  2016-02-19       Impact factor: 1.479

5.  Performance of a docking/molecular dynamics protocol for virtual screening of nutlin-class inhibitors of Mdmx.

Authors:  Nagakumar Bharatham; Kristin E Finch; Jaeki Min; Anand Mayasundari; Michael A Dyer; R Kiplin Guy; Donald Bashford
Journal:  J Mol Graph Model       Date:  2017-02-24       Impact factor: 2.518

6.  Monitoring Ligand-Induced Protein Ordering in Drug Discovery.

Authors:  Christy R Grace; David Ban; Jaeki Min; Anand Mayasundari; Lie Min; Kristin E Finch; Lyra Griffiths; Nagakumar Bharatham; Donald Bashford; R Kiplin Guy; Michael A Dyer; Richard W Kriwacki
Journal:  J Mol Biol       Date:  2016-01-23       Impact factor: 5.469

7.  Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction.

Authors:  Mariell Pettersson; Maria Quant; Jaeki Min; Luigi Iconaru; Richard W Kriwacki; M Brett Waddell; R Kiplin Guy; Kristina Luthman; Morten Grøtli
Journal:  PLoS One       Date:  2015-10-01       Impact factor: 3.240

Review 8.  Identification of inhibitors of biological interactions involving intrinsically disordered proteins.

Authors:  Daniela Marasco; Pasqualina Liana Scognamiglio
Journal:  Int J Mol Sci       Date:  2015-04-02       Impact factor: 5.923

9.  8-Triazolylpurines: Towards Fluorescent Inhibitors of the MDM2/p53 Interaction.

Authors:  Mariell Pettersson; David Bliman; Jimmy Jacobsson; Jesper R Nilsson; Jaeki Min; Luigi Iconaru; R Kiplin Guy; Richard W Kriwacki; Joakim Andréasson; Morten Grøtli
Journal:  PLoS One       Date:  2015-05-05       Impact factor: 3.240

10.  Delineating Substrate Diversity of Disparate Short-Chain Dehydrogenase Reductase from Debaryomyces hansenii.

Authors:  Arindam Ghatak; Nagakumar Bharatham; Anirudh P Shanbhag; Santanu Datta; Janani Venkatraman
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.